预约演示
更新于：2025-11-29
Cefiderocol Sulfate Tosylate
头孢地尔
更新于：2025-11-29
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评快速通道 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C30H34ClN7O10S2 |
InChIKeyDBPPRLRVDVJOCL-FQRUVTKNSA-N |
CAS号1225208-94-5 |
关联
26
项与 头孢地尔 相关的临床试验CTIS2024-516232-10-00
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
开始日期2025-12-01 |
NCT07004049
TREAT-GNB [CR-GNB]
TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria.
In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.
In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.
开始日期2025-04-21 |
申办/合作机构 |
TCTR20240718005
A Multicenter, Single-arm, Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Cefiderocol in Hospitalized Pediatric Patients from Birth to less than 3 Months of Age with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections
开始日期2024-11-01 |
申办/合作机构 |
100 项与 头孢地尔 相关的临床结果
登录后查看更多信息
100 项与 头孢地尔 相关的转化医学
登录后查看更多信息
100 项与 头孢地尔 相关的专利（医药）
登录后查看更多信息
896
项与 头孢地尔 相关的文献（医药）2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Pseudomonas guariconensis Necrotizing soft tissue infection, Denmark
Article
作者: Nielsen, Allan Evald Væver ; Calum, Henrik Pierre ; Monrad, Nina Elisabeth Pontoppidan ; Ehlers-Hansen, Jacob ; Soltau, Sofus Rønne
PATIENT AND METHODS:
A 72-year-old man presented to the emergency department with a 3-day history of fever, pain in the right leg/foot and general malaise. He was diagnosed with NSTI, empirical meropenem and clindamycin was started, and surgery was quickly performed with removal of all dead skin and subcutaneous tissue. All fasciae were intact.
RESULTS:
Blood cultures and tissue samples showed growth of Pseudomonas guariconensis, which a literature review revealed to be highly suspicious of meropenem resistance. This prompted quick change of antibiotics, first with ciprofloxacin and metronidazole added and then change of meropenem to cefiderocol. Susceptibility tests on both blood and tissue samples revealed resistance to meropenem (along with resistance to many other antibiotics). The patient improved, was changed to ceftazidim and ciprofloxacin and recovered fully from the infection.
CONCLUSIONS:
Since clindamycin has no effect on any Pseudomonas species and since Pseudomonas guariconensis has been resistant to meropenem in all reported cases, clinicians and microbiologists should treat these patients with extreme care.
2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Rapid detection of susceptibility to the ceftazidime-avibactam/aztreonam combination and cefiderocol in MBL-producing Enterobacterales by MALDI-TOF MS and turbidimetry
Article
作者: Torres, Ignacio ; Camacho, Jorge ; Colomina, Javier ; Cano, Sofía ; Belizón, Blanca ; Sánchez, David ; Navarro, David ; Poirel, Laurent ; de Michelena, Paula
INTRODUCTION:
Metallo-β-lactamase (MBL)-producing Enterobacterales pose a critical therapeutic challenge due to limited treatment options and high associated mortality. Aztreonam (ATM) combined with avibactam (AVI) and cefiderocol (FDC) are the recommended treatment strategies; however, standard methods for assessing aztreonam/ceftazidime-avibactam (ATM-CZA) synergy and FDC susceptibility are time-consuming and not widely implemented. In this context, the objective of this study was to evaluate whether matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and turbidimetry could serve as rapid, reliable tools for assessing susceptibility to ATM-CZA and FDC in MBL-producing Enterobacterales.
METHODS:
Thirty-eight clinical MBL-producing isolates were tested. Potential ATM-CZA synergy and FDC susceptibility were assessed using a broth disk elution protocol adapted for MALDI-TOF MS and turbidimetric analysis. Results were compared against reference methods: cross-gradient strips for synergy and EUCAST-standardized techniques for FDC susceptibility. Agreement, sensitivity, specificity, and ROC analyses were performed.
RESULTS:
MALDI-TOF MS achieved 100 % categorical agreement (CA) with the reference method for synergy detection after eight hours of incubation using standard inoculum. FDC susceptibility was correctly identified with 87 % CA within six to eight hours. Turbidimetry also showed strong performance, with up to 93.3 % CA for susceptibility to the ATM-CZA combination and 91.3 % for FDC, demonstrating statistically significant discrimination in absorbance values at six to eight hours.
CONCLUSION:
MALDI-TOF MS and turbidimetry offer accurate and rapid alternatives for the phenotypic detection of susceptibility to the ATM-CZA combination and FDC in MBL-producing Enterobacterales. These methods may enhance early antimicrobial decision-making in clinical microbiology laboratories.
2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
In vitro activity of essential antimicrobial agents, including ceftazidime/avibactam, imipenem/relebactam, and cefiderocol, against carbapenem-resistant Gram-negative bacteria primarily harboring the IMP-type carbapenemase gene in the Kinki region of Japan
Article
作者: Komatsu, Masaru ; Kuchibiro, Tomokazu ; Sawa, Kana ; Niki, Makoto ; Nakamura, Akihiro ; Yamasaki, Katsutoshi ; Nakamura, Tatsuya
OBJECTIVE:
In cases of infections caused by multidrug-resistant Gram-negative bacilli (MRGNB), the efficacy of various antimicrobial agents may be limited due to antimicrobial resistance. This study evaluated the antimicrobial activity of various antimicrobials, principally novel beta-lactam beta-lactamase inhibitor combinations, against MRGNB prevalent in the Kinki region of Japan.
METHODS:
A total of 207 strains were utilized in the study, encompassing 108 carbapenemase-producing Enterobacterales (CPE) strains, 9 carbapenemase-non-producing carbapenem-resistant Enterobacterales (non-CP-CRE) strains, 73 carbapenem-resistant Pseudomonas aeruginosa (CRPA) strains, and 17 carbapenem-resistant Acinetobacter spp. (CRA) strains. These strains were obtained from the Study of Bacterial Resistance in the Kinki Region of Japan. Antimicrobial susceptibility testing was assessed via broth microdilution, with MICs determined according to the Clinical and Laboratory Standards Institute standards.
RESULTS:
The MIC50/MIC90 values (in μg/mL) for each antimicrobial agent were determined for the CPE, non-CP-CRE, CRPA, and CRA strains. The following agents demonstrated activity: ceftazidime/avibactam (CAZ/AVI) (16/>16, 2/8, 8/16, 16/>16), piperacillin/tazobactam (8/>64, >64/>64, 64/>64, 8/>64), ceftolozane/tazobactam (CTLZ/TAZ) (>32/>32, 16/>32, 8/>32, >32/>32), imipenem/relebactam (IPM/REL) (0.25/4, 1/2, 8/>8, >8/>8), tigecycline (≤0.5/2, 1/8, >8/>8, ≤0.5/1), colistin (1/2, 1/8, 1/1, 1/2), and cefiderocol (0.25/2, 1/16, 1/8, 0.5/32).
CONCLUSION:
The MIC distributions for colistin, tigecycline, and cefiderocol were narrow across resistant strains, indicating consistent activity. Furthermore, the MIC distributions of CAZ/AVI and IPM/REL exhibited a narrow range of concentrations against non-CP-CRE and non-CP-CRPA, respectively. In contrast, CTLZ/TAZ exhibited a similarly narrow distribution against non-CP-CRPA. These findings suggest that these antimicrobials effectively treat infections caused by MRGNB.
75
项与 头孢地尔 相关的新闻（医药）2025-11-26
·感染视界
多重耐药菌的日益蔓延已成为全球公共卫生领域的重大危机，其中革兰阳性菌和革兰阴性菌的威胁尤为严峻。前者因其强大的适应性与传播力，后者则凭借其复杂的耐药机制（如产超广谱β-内酰胺酶、碳青霉烯酶）及低外膜通透性，使得传统抗生素疗效殆尽，常导致临床治疗陷入无药可用的困境。
为应对这一难题，2022 年10月国家卫生健康委员会等13个部委再次发布《遏制微生物耐药国家行动计划（2022—2025年）》， 其中“推动新型抗微生物药物的研发与转化应用” 被列入主要任务之一。
近年来国际上新抗菌药物包括对耐药菌有效药物的研发在经历低谷后又逐渐趋热，目前有哪些新型抗菌药处于临床研究阶段，一起来看看吧。
01
对耐药革兰阴性菌有效的新抗菌药物
1. 头孢洛扎—他唑巴坦
头孢洛扎结构与头孢他啶相似，侧链的吡唑环和2-氨基乙烷基增加了头孢洛扎对AmpC酶的稳定性，增强与铜绿假单胞菌青霉素结合蛋白的亲和力以及外膜的通透性。
头孢洛扎-他唑巴坦对肠杆菌目、假单胞菌属，以及脆弱拟杆菌等厌氧菌均具良好抗菌活性，包括产超广谱β内酰胺酶（ESBL）大肠埃希菌和多重耐药（MDR）铜绿假单胞菌。
2014年美国FDA和欧洲EMA批准该药用于治疗成人复杂性腹腔感染（cIAI）、复杂性尿路感染 （cUTI）和医院获得性肺炎（HAP）。 用法为：
治疗cIAI和cUTI时1.5g，每8小时1次。
治疗HAP[包括呼吸机相关性肺炎（VAP）] 时3.0g，每8小时1次，静脉滴注。
2. 头孢他啶—阿维巴坦
阿维巴坦为新型β内酰胺酶抑制剂，主要对包括KPC在内的A类丝氨酸酶、C类（AmpC） 和部分D类酶（OXA-48等）具有抑制作用，但对B类金属酶无效。主要用于治疗产KPC酶的肠杆菌科细菌的感染。
随着头孢他啶-阿维巴坦临床广泛应用，该药在使用过程中碳青霉烯类耐药肺炎克雷伯菌（CRKP）菌株诱导耐药问题也屡见报道，主要是KPC-2型等原本敏感的酶型发生了基因突变。头孢他啶-阿维巴坦还可用于治疗铜绿假单胞菌感染。
头孢他啶和阿维巴坦药代动力学参数值相似，头孢他啶的血浆蛋白结合率＜10%，阿维巴坦的血浆蛋白结合率为5.7%～8.2%；两者均80%以上以原型形式经肾排泄，半衰期分别为2.5h和2.8h。
头孢他啶-阿维巴坦在美国及欧洲分别于2015年及2016年上市，被批准用于治疗cIAI、HAP/VAP及cUTI ；2019年中国批准上市，适应证为cIAI，HAP/VAP；在欧洲及中国尚批准用于在治疗方案选择有限的成人患者中治疗革兰阴性菌引起的感染。
用法为2.5g（头孢他啶2.0g、阿维巴坦0.5g），每8小时1次，静脉滴注。
3. 美罗培南—韦博巴坦
韦博巴坦同样为ESBL、KPC、C类β内酰胺酶的抑制剂，对金属酶及D类酶无抑制作用。
8mg/L韦博巴坦可降低美罗培南对产ESBL、KPC的肠杆菌目细菌的MIC 1/16～1/128，使美罗培南耐药菌株恢复敏感性。但韦博巴坦不能降低美罗培南对耐药鲍曼不动杆菌和铜绿假单胞菌的MIC。
美罗培南- 韦博巴坦于2017年8月底被美国FDA批准用于治疗成人cUTI，用量为美罗培南-韦博巴坦（2g-2g） 每8小时1次，静脉滴注。
4. 亚胺培南—西司他丁—雷利巴坦
雷利巴坦化学结构与阿维巴坦相似，可抑制A类和C类β内酰胺酶。体外药敏试验中，4mg/L雷利巴坦可降低亚胺培南对包括产 ESBL、KPC、AmpC、OXA的肠杆菌目细菌的MIC，使大部分菌株恢复对亚胺培南的敏感性，但对金属酶无抑制作用。
雷利巴坦（≥4mg/L）可恢复部分耐药铜绿假单胞菌（产AmpC酶菌株）对亚胺培南的敏感性。
雷利巴坦主要经肾脏排泄，半衰期1.2h左右，肺泡上皮衬液浓度是血浆浓度的54% 。
2019年7月美国FDA批准用于治疗cIAI和cUTI，用法为亚胺培南-西司他丁-雷利巴坦1.25g （500mg-500mg-250mg）每6小时1 次。
5. 舒巴坦—杜洛巴坦
杜洛巴坦是新一代二氮杂二环辛烷（DBO）酶抑制剂， 对A、C和D类（包括丝氨酸酶OXA）β内酰胺酶具有很好的抑制作用。
舒巴坦-杜洛巴坦对鲍曼醋酸钙复合菌（ABC）显示出强大的体外活性，2023年5月美国FDA批准舒巴坦-杜洛巴坦用于治疗由 ABC 引起的成人HAP和VAP。
舒巴坦-杜洛巴坦的推荐剂量为静脉注射2g（1∶1），每6小时1 次。
6. 头孢地尔
头孢地尔为含儿茶酚侧链的铁螯合头孢菌素，主要作用靶点为革兰阴性菌细胞膜PBP3蛋白，儿茶酚侧链与铁离子结合，利用细菌细胞膜上铁载体进入细胞膜，与靶位结合抑制细菌胞膜合成。
头孢地尔蛋白结合率为40%～60%，肺泡上皮衬液浓度为血浆浓度的24%左右，90%以上以原型经肾脏排泄，半衰期为2～3h。
2019年底，头孢地尔被美国FDA批准上市， 适应证为cUTI，用量2g，每8小时1次，静脉滴注。
02
对耐药革兰阳性菌有效的新抗菌药物
康替唑胺是新型唑烷酮类药物，抗菌活性与利奈唑胺相仿，骨髓抑制等不良反应减少，是我国与全球同步研发的拥有自主知识产权的1类抗菌新药。
康替唑胺抗菌谱与利奈唑胺类似，对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的葡萄球菌，包括耐青霉素肺炎链球菌（PRSP）在内的链球菌属，包括VRE在内的肠球菌属，包括结核分枝杆菌、非结核分枝杆菌、诺卡菌属，以及芽孢杆菌属、棒状杆菌属和单核李斯特菌等细菌具抗菌活性。
康替唑胺口服的绝对生物利用度100%，半衰期（2.63±1.22）h；组织分布良好，肺、软组织、肌肉、骨髓穿透率高，表观分布容积0.61L/kg； 主要以代谢物形式随尿和粪便排泄；老年或肾功能不全者无需调整给药剂量。
康替唑胺口服片剂2021年6月在中国首先获批上市用于治疗皮肤软组织感染，用法为800mg，每12小时1次；目前静脉制剂正在进行Ⅲ期临床试验。
参考文献：
[1]秦晓华,郝敏,王明贵. 新抗菌药物研究进展 [J]. 中国感染与化疗杂志, 2024, 24 (04): 489-496. DOI:10.16718/j.1009-7708.2024.04.018.
上市批准微生物疗法临床研究
2025-11-22
·今日头条
重症医学
摘要 (Abstract): 肺炎克雷伯菌（Klebsiella pneumoniae, KP）是重要的机会性病原体。然而，一种被称为高毒力肺炎克雷伯菌（hvKP）的独特致病变种在过去三十年间崛起并迅速全球蔓延。hvKP与经典KP菌株显著不同，其能够导致健康个体发生严重的社区获得性感染，典型表现为化脓性肝脓肿（PLA），并常伴有灾难性的转移性感染，如内源性眼内炎和中枢神经系统感染。hvKP的高致病性源于其特有的毒力因子组合，包括高黏液型荚膜、高效铁载体系统（特别是气杆菌素和沙门菌素）以及特定的毒力质粒（如pLVPK）。当前的公共卫生面临的最严峻挑战是hvKP与多重耐药（MDR）表型的融合，特别是碳青霉烯耐药高毒力肺炎克雷伯菌（CR-hvKP）的出现，导致了治疗选择极其有限且预后极差的感染。本文旨在综述hvKP的全球流行病学趋势、分子致病机制、典型的临床表现及诊断线索，并深入探讨当前“毒力与耐药性融合”的挑战，为临床实践和未来研究提供全面视角。
1. 引言 (Introduction)
肺炎克雷伯菌（Klebsiella pneumoniae, KP）是一种常见的革兰氏阴性条件致病菌，广泛定植于人类胃肠道和上呼吸道。传统上，经典肺炎克雷伯菌（classical K. pneumoniae, cKP）主要导致免疫功能低下或伴有基础疾病的住院患者发生机会性感染，如尿路感染、肺炎和菌血症。
然而，自20世纪80年代中期以来，一种更具侵袭性的KP变种——高毒力肺炎克雷伯菌（Hypervirulent K. pneumoniae, hvKP）——首先在环太平洋地区（如台湾）被识别。hvKP以其独特的致病谱而闻名，能够在既往健康的社区人群中引起严重的社区获得性感染，最典型的特征是原发性化脓性肝脓肿（Pyogenic Liver Abscess, PLA），并伴有高比例的血行播散至远处器官，导致毁灭性的转移性感染，如内源性眼内炎、脑膜炎和脑脓肿。
在过去的几十年里，hvKP已从区域性地方病演变为全球性的健康威胁。更令人担忧的是，hvKP正与全球范围内的多重耐药（MDR）菌株，特别是碳青霉烯耐药（CR）菌株进行遗传物质交换，催生出“毒力-耐药融合”的碳青霉烯耐药高毒力肺炎克雷伯菌（CR-hvKP）。这类兼具高致病性和广泛耐药性的超级细菌，使得感染的治疗极其困难，病死率显著升高，对全球公共卫生构成前所未有的严峻挑战。本文将对hvKP的流行病学、致病机制、临床特征、诊断线索及其毒力与耐药融合的最新进展进行全面综述。
2. hvKP的定义与鉴定 (Definition and Identification of hvKP)
对hvKP的准确定义和鉴定是理解其致病性和流行病学的基础。
2.1 表型特征：高黏液表型与拉丝试验 hvKP最显著的特征是其在琼脂平板上形成的菌落具有高度黏稠性，即“高黏液表型”（Hypermucoviscosity, HM）。这一表型可通过简便的“拉丝试验”（String Test）进行初步评估：用接种环触碰菌落并垂直向上拉起，若能形成长度大于5mm的黏性细丝，则判定为阳性。然而，拉丝试验并非hvKP的特异性或敏感性金标准，因为部分hvKP菌株可能呈阴性，而某些cKP菌株也可呈阳性。因此，需要结合分子生物学方法进行确诊。
2.2 基因型特征：关键毒力基因与血清型 分子层面的鉴定更为精确。hvKP的核心特征是其携带一系列特定的毒力基因，这些基因通常位于一个大型毒力质粒（如原型质粒pLVPK）上。关键分子标志物包括：
铁载体基因：主要指编码气杆菌素（Aerobactin）的iuc基因簇和编码沙门菌素（Salmochelin）的iro基因簇。气杆菌素是hvKP最重要的分子标志物之一，其存在对致病性至关重要。
黏液表型调节基因：主要为rmpA及其同系物rmpA2，这些基因通过正向调节荚膜多糖的合成来促进高黏液表型的形成。
此外，特定的荚膜血清型与hvKP的高度侵袭性密切相关。K1和K2血清型在hvKP菌株中占据主导地位，尤其是K1型，被认为是PLA和转移性感染中最常见的类型。
3. 流行病学特征 (Epidemiological CHAracteristics)
hvKP的流行病学已从地方性向全球性转变。
3.1 全球传播与高危区域 hvKP最初集中在环太平洋亚洲地区，如中国大陆、台湾地区、韩国和东南亚。然而，近年来，北美、欧洲、南美和澳大利亚等非亚洲地区关于hvKP感染的报道显著增加，证实了其全球蔓延的趋势。尽管如此，亚洲人群，特别是华人，似乎仍表现出更高的感染易感性。
3.2 宿主危险因素 糖尿病是hvKP感染最重要且公认的宿主危险因素。高血糖环境可能通过削弱中性粒细胞吞噬功能、影响细胞免疫以及促进细菌荚膜多糖合成，从而增加感染风险。其他潜在风险因素包括酗酒、肝胆系统疾病、恶性肿瘤以及免疫抑制状态。
3.3 传播模式 hvKP感染主要表现为社区获得性（Community-Acquired, CA）感染，通常源于患者自身的胃肠道定植菌。然而，随着hvKP在医疗机构中的出现，以及与MDR菌株的基因交流，医院获得性（Hospital-Acquired, HA）和医疗照护相关性（Healthcare-Associated, HCA）hvKP感染的比例正在逐步上升，提示其传播模式日趋复杂。
4. 致病机制与毒力因子 (Pathogenesis and Virulence Factors)
hvKP的高度致病性源于其独特的毒力因子组合，这些因子协同作用使其能够有效逃避宿主免疫并高效获取生存所需营养。
4.1 荚膜多糖 (Capsular Polysaccharide, CPS) 荚膜是hvKP最重要的毒力决定簇。K1和K2型荚膜，尤其是在hvKP中常见的类型，具有极强的抗吞噬能力和抗血清杀菌活性，是抵抗宿主天然免疫防御的第一道屏障。荚膜的存在使得细菌能够在宿主环境中生存并繁殖。
4.2 高黏液表型调节因子 (RmpA/RmpA2) rmpA (regulator of mucoid phenotype A) 及其同系物rmpA2 是转录激活因子，它们通常编码于毒力质粒上。这些基因正向调节荚膜多糖的生物合成，导致菌株呈现出显著的高黏液表型，增强了细菌的抗吞噬能力，是hvKP侵袭性的关键因素之一。
4.3 铁载体系统 (Siderophore Systems) 铁是细菌生长不可或缺的微量元素，但在宿主体内以高度结合的形式存在。hvKP进化出高效的铁载体系统以在限铁环境中获取铁。
气杆菌素 (Aerobactin): 被广泛认为是hvKP致病性中最关键的铁载体。由iucABCD和iutA基因簇编码，具有极高的铁亲和力，并在低铁环境下高效运作。其检测是区分hvKP与cKP的重要分子标志。
沙门菌素 (Salmochelin): 是肠杆菌素的糖基化衍生物，能够逃避宿主脂质运载蛋白-2 (Lcn2) 的结合，从而更有效地获取铁。
耶尔森菌素 (Yersiniabactin): 虽然在cKP中也常见，但在hvKP中高表达，有助于细菌在不同组织部位（如呼吸道）的定植和感染。
4.4 毒力质粒 (Virulence Plasmid) 多数hvKP菌株的毒力基因，如rmpA/A2、iuc和iro基因簇，通常不位于染色体上，而是携带在一个大型的（约200kb）非接合型毒力质粒上，以pLVPK为代表。该毒力质粒的存在是hvKP致病性的核心，并可促进这些毒力基因在菌株间的传播。
5. 临床表现与诊断线索 (Clinical Manifestations and Diagnostic Clues)
hvKP感染的临床特征是其高度侵袭性和多器官转移倾向，临床医生需高度警惕其独特的表现。
5.1 典型的临床综合征
化脓性肝脓肿 (Pyogenic Liver Abscess, PLA): 这是hvKP感染最经典的表现，常发生于无肝胆基础疾病的糖尿病患者。患者常有急性起病的高热、寒战、右上腹疼痛和触痛。
侵袭性肺炎： hvKP可引起严重的社区获得性肺炎，特点是起病急骤、病情进展迅速，可能发展为坏死性肺炎，部分患者可咳出特征性的砖红色胶冻样痰。
原发性菌血症和脓毒症： 在许多非亚洲地区，hvKP感染可表现为严重的社区获得性菌血症和脓毒症，而不一定伴有明显的肝脓肿。
5.2 转移性感染：hvKP的危险信号 这是hvKP最可怕的特征，细菌从原发灶（如肝脏或肠道）经血流播散至远处器官。
内源性眼内炎 (Endogenous Endophthalmitis): 这是PLA患者最常见且严重的并发症，常导致不可逆的视力丧失甚至眼球摘除。任何克雷伯菌菌血症或肝脓肿患者出现视力模糊、眼痛、结膜充血等眼部症状，均应视为眼科急症。
中枢神经系统感染：包括脑膜炎和脑脓肿，表现为剧烈头痛、意识障碍、颈项强直等，致死率和致残率极高。
其他转移部位：包括前列腺脓肿、皮肤软组织感染（如坏死性筋膜炎）、骨髓炎和关节感染等。
5.3 临床诊断线索与确诊流程 (Clinical Diagnostic Clues and Confirmation Process) 肺炎克雷伯菌感染的诊断依赖于临床表现、非特异性炎症指标和微生物学证据。对于hvKP，识别其独特线索至关重要。
5.3.1 临床体征与症状线索
急骤起病与高热：患者通常急性起病，体温常高于39℃，伴明显毒血症表现。
肝区疼痛与触痛：不明原因发热伴右上腹疼痛、肝区叩击痛时，应高度怀疑PLA。
转移性感染迹象：这是hvKP感染最强的临床提示。克雷伯菌菌血症或肝脓肿患者若出现视力障碍、眼痛、眼部充血、剧烈头痛、意识障碍、颈项强直等症状，应立即启动相应检查，紧急评估眼内炎或中枢神经系统感染。
5.3.2 实验室化验检查
常规血液检查：患者常有显著的白细胞计数升高（中性粒细胞为主），伴核左移。C-反应蛋白（CRP）和降钙素原（PCT）水平通常极高，提示严重的全身炎症反应。
肝功能检查： PLA患者常见血清碱性磷酸酶（ALP）和谷氨酰转肽酶（GGT）显著升高，转氨酶轻至中度升高。
微生物学确诊（金标准）： 从临床标本中分离并鉴定出肺炎克雷伯菌是确诊依据。
标本采集： 在抗生素治疗前，必须采集血液培养。根据感染部位，还应采集脓液（如肝脓肿穿刺液）、痰液、尿液、脑脊液或玻璃体液等进行培养。
鉴定与药敏：实验室通过生化试验、质谱（MALDI-TOF MS）等方法鉴定菌种，并进行药物敏感性试验指导临床用药。对于高度怀疑hvKP的分离株，应加做拉丝试验和毒力基因（如iucA、rmpA）PCR检测，以及荚膜血清型（K1/K2）检测。
5.3.3 影像学检查 影像学对于确定感染灶范围和发现隐匿的转移灶至关重要。
腹部影像学：腹部超声是筛查PLA的快速方法。腹部增强CT是诊断PLA的金标准，可见肝内低密度灶，脓肿壁环形强化，有时可见气体影。
胸部影像学： 胸部CT用于评估肺炎严重程度，识别坏死、空洞形成或脓胸。
其他部位： 对于有相应症状的患者，需积极进行头颅MRI/CT排除脑脓肿或脑膜炎；眼部B超用于评估玻璃体混浊和眼内炎；MRI可用于诊断深部软组织感染或骨髓炎。
6. 当前危机：毒力与耐药性的融合 (The Convergence of Virulence and Resistance)
传统观念认为hvKP菌株对多数抗生素敏感，而MDR菌株毒力相对较低。然而，这种“毒力-耐药性分离”的格局正在被打破，催生了致命性的CR-hvKP。
6.1 碳青霉烯耐药高毒力肺炎克雷伯菌 (CR-hvKP) 的出现 CR-hvKP的出现是当前全球公共卫生领域最紧迫的危机之一。这种融合主要通过两种遗传机制发生：
敏感hvKP菌株获得耐药性质粒： 原本敏感的hvKP菌株通过接合等方式，获得携带碳青霉烯酶基因（如blaKPC, blaNDM, blaOXA-48等）的耐药质粒。
MDR-KP菌株获得毒力质粒： 经典的MDR菌株，特别是全球流行的碳青霉烯耐药高风险克隆（如ST11或ST258），通过质粒接合或重组，获得了pLVPK样毒力质粒。
尤其在中国，ST11型碳青霉烯耐药肺炎克雷伯菌获得毒力质粒，演变为ST11型CR-hvKP的报道引起了极大的关注。这类融合型菌株同时具备高侵袭性和广泛耐药性，导致感染病死率显著增加，给临床治疗带来了巨大挑战。
7. 治疗策略与挑战 (Treatment Strategies and Challenges)
hvKP感染的治疗，特别是CR-hvKP的治疗，是临床上的巨大难题。
7.1 抗感染治疗
敏感hvKP： 对于对碳青霉烯敏感的hvKP感染，第三/四代头孢菌素、氟喹诺酮类或β-内酰胺类/β-内酰胺酶抑制剂复合物通常有效。对于严重感染，特别是涉及中枢神经系统或眼部的转移性感染，碳青霉烯类药物常被视为首选。
CR-hvKP： 治疗极其棘手，选择严重受限。治疗方案必须基于严格的体外药敏试验，并常需要联合用药。
新型酶抑制剂复方制剂： 如头孢他啶/阿维巴坦（Ceftazidime-avibactam）对产KPC型碳青霉烯酶的菌株具有较好疗效，但对产金属-β-内酰胺酶（如NDM）的菌株无效。
多黏菌素（Polymyxins）和替加环素（Tigecycline）： 传统上被用作治疗MDR革兰氏阴性菌感染的“最后防线”药物，但其肾毒性、神经毒性以及在肺部、脑脊液穿透力不佳等缺点限制了其应用。
其他新型抗生素： 如头孢地尔（Cefiderocol）等在治疗CR-hvKP感染方面显示出潜力，但需更多临床数据支持。
个体化治疗： 基于患者基础疾病、感染部位、菌株药敏结果以及当地流行病学特征，制定个体化的抗感染方案。
7.2 感染源控制 对于化脓性肝脓肿、深部软组织感染或脑脓肿，单纯的药物治疗往往不足。积极的感染源控制至关重要，包括：
经皮穿刺引流： 对于肝脓肿等深部脓肿，超声或CT引导下的经皮穿刺引流是有效的治疗手段。
外科清创： 对于坏死性筋膜炎或大的脓肿，外科手术清创和引流必不可少。
眼科急症处理： 怀疑内源性眼内炎时，需立即请眼科会诊，进行玻璃体腔内注射抗生素，有时甚至需要玻璃体切除术以挽救视力。
8. 结论与展望 (Conclusion and Future Perspectives)
高毒力肺炎克雷伯菌已然成为一个全球性、不断演进的严重健康威胁。其独特的侵袭性，特别是在社区人群中引起的肝脓肿和转移性感染，需要临床医生高度警惕。当前最严峻的挑战是hvKP与多重耐药，尤其是碳青霉烯耐药性的融合，导致了CR-hvKP这一“超级细菌”的出现，极大地增加了感染的病死率和治疗难度。
未来的研究和公共卫生策略应集中在以下几个方面：
加强全球监测与基因组学研究： 建立全球性的监测网络，利用全基因组测序（WGS）等先进技术，追踪高风险hvKP克隆株和耐药质粒的传播与演化路径。
开发快速诊断工具： 迫切需要开发能够在临床床旁快速准确识别hvKP，特别是CR-hvKP的诊断方法，以指导早期、精准的治疗。
探索非抗生素治疗策略： 鉴于抗生素耐药性的严峻形势，应积极探索抗生素替代疗法，包括针对荚膜、铁载体等毒力因子的单克隆抗体或小分子抑制剂、噬菌体疗法，以及疫苗的研发，以期从根本上解决hvKP的威胁。
优化感染控制措施： 制定和实施更有效的院感控制策略，以限制hvKP在医疗机构内的传播，并减少耐药基因与毒力基因交流的机会。
面对不断演变的hvKP，全球医学界、公共卫生机构和制药工业必须加强合作，共同应对这一严峻挑战，以保护人类健康。
2025-11-17
Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review
抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述
Konstantinos Alexakis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771,
2
To be or not to be: the non-antimicrobial properties of common antimicrobials
生存还是毁灭：常见抗菌药物的非抗菌特性
Shivakumar Narayanan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783,
SYSTEMATIC REVIEWS（系统综述）
3
Antibiotic-induced Bartter-like syndrome: a systematic review
抗生素诱发的巴特综合征样表现：系统综述
Megha Priyadarshi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791,
4
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review
两性霉素B脂质体预防性用药在儿科中的应用：系统综述
Emma V Thorley and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802,
ORIGINAL RESEARCH（论著）
5
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究
Sarah F Hak and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812,
6
Plasmodium falciparum isolates: ex vivo drug response
恶性疟原虫分离株：体外药物反应
Edem Adika and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822,
7
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia
低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827,
8
Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England
探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法
Ming Xuan Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836,
9
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study
新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究
Yulia Butscheid and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848,
10
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析
Alessandro Cozzi-Lepri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859,
11
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model
基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型
Diego Vera-Yunca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868,
12
Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine
线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关
J R Macdonald and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877,
13
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium
米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性
Kay Htaik and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884,
14
Early use of the novel antifungal rezafungin: a case series and literature review
新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述
H C Davidson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892,
15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach
基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量
Gisela Myrian de Lima Leite Dalla Rosa and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901,
16
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade
过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关
Aliya El Nagar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906,
17
An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections
一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响
Mariagrazia Ciardo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914,
18
Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估
Xiaoping Shi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925,
19
Rapid susceptibility testing on urine for antimicrobial stewardship in general practice
全科实践中的尿液快速药敏试验助力抗菌药物管理
Patrick D J Sturm and Tanja Schülin
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932,
20
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941,
21
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性
Marie L G Attwood and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946,
22
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions
中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性
Nadiia Mosiichuk and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950,
23
Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China
中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征
Zeqiang Zhan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963,
24
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study
根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集
Zhengyu Luo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971,
25
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus
抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响
Aliona S Rosca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979,
26
Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study
肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究
Lijuan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987,
27
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875
多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征
Jonathan Koong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992,
28
Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum
改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较
Doris Hillemann and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996,
29
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations
由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转
Paschalis Paranos and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006,
30
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France
瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构
Sofie M Edslev and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015,
31
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections
抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估
Nischal Ranganath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024,
32
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control
肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法
Ana Beatriz Gonçalves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031,
33
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori
抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性
Paweł Krzyżek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043,
34
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro
生殖支原体体外诱导产生的新型阿奇霉素耐药突变
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050,
RESEARCH LETTERS（研究信函）
35
Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations
婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度
Jeffrey Harrington and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053,
36
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis
两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法
Natacha Mrozek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056,
37
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？
Alexandra Morin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058,
LETTER TO THE EDITOR（致编辑的信）
38
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint
单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点
Miguel Villamarín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 8
抗菌化疗杂志 80卷 8期
https://academic.oup.com/jac/issue
Review(综述)
1
World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’
世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇”
Vazhayil Hari Krishnaprasad and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069
Original Research(论著)
2
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023)
氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结
Helio S Sader and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079
3
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究
Hitoshi Kawasuji and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091
4
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium
缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析
Yukitaka Hayashi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099
5
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial
为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验
Nusrat Shafiq and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108
6
An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型
Cole McGrath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116
7
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa
黏液型铜绿假单胞菌纸片扩散法的优化与改进
Aixin Wang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125
8
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查
Christine Watera and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134
9
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究
Sharana Mahomed and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144
10
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study
接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究
Javier García-Abellán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157
11
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model
慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究
Midas B Mulder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168
12
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据
Roberta Gagliardini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178
13
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验
Hsin-Yun Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186
14
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia
青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究
Pernilla Kihlberg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193
15
Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202
16
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway
齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌
Yun-Dan Zheng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213
17
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study
阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究
Tom C Zwart and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225
18
48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析
Elisa de Lazzari and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233
19
The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time
多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响
Trenton Honda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240
20
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales
一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估
Christian Moguet and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246
21
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes
粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究
Matteo Rinaldi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256
22
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染
Robin H G A van den Biggelaar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268
23
Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279
24
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy
意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件
Andrea Brenciani and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284
25
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022
2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征
Corentin Poignon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294
26
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections
具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁
Ye Jin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304
27
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性
Simon E Koele and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313
28
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study
头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究
Dimitrios Basoulis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322
Research Letters(研究信件)
29
Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring
达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告
Carlo Pallotto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324
30
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs
韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174）
Hyeonwoo Cho and Kun Taek Park
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326
31
Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report
时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告
Layla Pagnucco and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330
32
Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48
土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征
Astrid Rasmussen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331
Letters to the Editor(致编辑的信)
33
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital
述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究
Jianjun Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332
34
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response
产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复
Gulhadiye Avcu
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333
Corrections(更正)
35
Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)
更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334
36
Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335
37
Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics
更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2
抗菌化疗杂志 80卷 增刊2期
https://academic.oup.com/jac/issue
SUPPLEMENT (补充)
CANWARD 2007-23
加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告
Foreword(前言)
1
The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection
加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集
James C Hurley and Jean-Yves Madec
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1
Supplement Papers(补充论文)
2
Seventeen years of the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究17年（2007-2023年）
George G Zhanel and Heather J Adam
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4
3
Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14
4
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26
5
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023）
Anissa Brahami and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34
6
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23）
Heather J Adam and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44
7
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023
Philippe Lagacé-Wiens and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53
8
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23）
Laura F Mataseje and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61
9
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23)
加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23）
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71
10
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23)
加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果
Andrew Walkty and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82
Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Classifying patients with invasive fungal disease: towards a unified case definition?
侵袭性真菌病患者分类：能否达成统一的病例定义？
Mehmet Ergün and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343,
SYSTEMATIC REVIEW（系统综述）
2
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis
早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析
ZhaoYi Tan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360,
ORIGINAL RESEARCH（论著）
3
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium
屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定
Maria Laura Ferrando and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368,
4
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响
Rebecka Papaioannu Borjesson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374,
5
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响
Parul Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383,
6
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据
So Yun Lim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390,
7
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme
摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准
Aymeric Jacquemin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398,
8
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya
2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征
Diana Imoli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407,
9
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响
Tao-Hung Ou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416,
10
Safety of topical tobramycin powder during operative treatment of fractures
骨折手术中使用局部妥布霉素粉末的安全性
Gregory M Schrank and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420,
11
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析
Rinko Lau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427,
12
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England
从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌
Satheesh Nair and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432,
13
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics
克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用
Siddharth Singh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441,
14
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446,
15
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo
DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用
Xuemin Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458,
16
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology
采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究
Joseph Meletiadis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465,
17
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study
万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析
M Del Monte and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473,
18
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient
异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现
Martyna Pociupany and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483,
19
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486,
20
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database
使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析
Yongseop Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495,
21
Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
2024年中国河南省HIV-1感染者传播耐药情况
Jinjin Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502,
22
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性
Makiko Noda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512,
23
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization
头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征
Clara Moretó-Castellsaguéand others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523,
24
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates
达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529,
25
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation
伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响
Wenjie Cui and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540,
26
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up
加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响
Freshwork Ayalew Abegaz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549,
RESEARCH LETTERS（研究快信）
27
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient
治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染
Giovanni Mulé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552,
28
Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage
城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759
Xinyuan Qiu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555,
29
Characterization of multiresistance gene optrA in Bacillus subtillis from China
中国枯草芽孢杆菌中多重耐药基因optrA的特征分析
Yongliang Che and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557,
30
Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China
从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征
Fuqiang Ye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560,
LETTERS TO THE EDITOR（致编辑的信）
31
Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events
关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论
Mi Zhou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562,
32
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study
关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论
Satoru Mitsuboshi
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563,
33
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response
住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead
长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586,
2
Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估
James C Hurley
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596,
SYSTEMATIC REVIEWS（系统综述）
3
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
研究肺结核治疗的肺内药代动力学：方法学的系统综述
Isabella van der Feltz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608,
4
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis
全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析
Christopher Larkin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621,
ORIGINAL RESEARCH（研究论著）
5
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？
Paula Bierge and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629,
6
Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023
2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测
Nguyen Van Thanh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634,
7
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia
哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性
Savan Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643,
8
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia
连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度
Claire Roger and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653,
9
Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial
头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验
Tamara Klementová and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658,
10
Trends in antifungal use among hospitalized patients in the USA, 2018–23
2018-2023年美国住院患者抗真菌药物使用趋势
Dallas J Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664,
11
Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study
BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究
Louis Oudiane and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675,
12
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium
甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性
Sofie Skovmand and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681,
13
A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model
基于群体药代动力学模型的左氧氟沙星剂量方案先验优化
Emmanuel Enard and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692,
14
Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析
Tingting Wu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704,
15
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria
开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标
Irene Zaghi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713,
16
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718,
17
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验
Jinhee Jo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726,
18
Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application
抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示
Nathan Engel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731,
19
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741,
20
Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究
Hiroki Katsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751,
21
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
BALANCE临床试验中血流感染患者的临床病程
Sean W X Ong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758,
22
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study
神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究
Qian Zeng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772,
23
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781,
24
Population pharmacokinetics of bictegravir in real-world people with HIV
现实中HIV感染者比克替拉韦的群体药代动力学
Pierre Ekobena and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789,
25
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index
活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响
Teres Samuelsson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798,
26
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806,
27
Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model
在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移
Solene Labaye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813,
28
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用
Justin Halim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824,
29
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验
L Sagaon-Teyssier and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833,
30
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin
对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征
Emilia Cercenado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843,
31
Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA
美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构
Chih-Hao Hsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853,
32
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii
鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征
Jingchen Hao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861,
33
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征
Jing Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872,
RESEARCH LETTERS（研究快报）
34
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？
Giulia Turicchi and Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874,
35
The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii
catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876,
36
Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas
携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播
Roberto Sierra and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879,
37
Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae
替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性
Julie Brousseau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881,
LETTERS TO THE EDITOR（致编辑的信）
38
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性
Karl Oldberg and Magnus Rasmussen
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883,
39
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究
Giancarlo Ceccarelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885,
40
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response
住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886,
Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷 增刊4期
https://academic.oup.com/jac/issue/80/Supplement_4
SUPPLEMENT（补充）
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
FOREWORD（前言）
1
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
James C Hurley and Alan P Johnson
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1,
SUPPLEMENT PAPERS（补充论文）
2
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions
英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向
Alasdair P MacGowan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6,
3
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations
英国抗菌化疗学会耐药性监测项目：方法与局限性
Michael Allen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21,
4
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35,
5
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48,
6
Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019
英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59,
7
Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019
英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71,
8
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019)
英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年）
Carolyne Horner and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86,
9
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future
英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来
Benjamin J Parcell and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期
https://academic.oup.com/jac/issue
VIEWPOINTS（观点）
1
Modification of antimicrobial susceptibility testing methods
抗菌药物敏感性检测方法的修改
Ian Morrissey and Jean B Patel
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888,
2
Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA
观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验
Ashley M Wilde and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891,
REVIEWS（综述）
3
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式
Cleo Anastassopoulou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901,
4
Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications
融合质粒的分子驱动因素：机制见解与进化意义
Ziyi Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911,
ORIGINAL RESEARCH（研究论著）
5
Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry
泰国养猪业中出现与牲畜相关的MRSA克隆复合体398
Pawarut Narongpun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917,
6
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告
Tomaso Beringheli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922,
7
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections
细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点
Yao Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933,
8
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus
acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用
Jiahui Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944,
9
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究
Thibaut Gelé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953,
10
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare
胞内分枝杆菌中与氯法齐明耐药相关的新型突变
Xiuzhi Jiang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957,
11
Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria
基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性
Mariana Romero-Gonzalez and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969,
12
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin
体外进化揭示生殖支原体对莫西沙星的耐药机制
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977,
13
The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening
毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性
Weifeng Xu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988,
14
Molecular insights into carbapenemase-producing Enterobacterales from Senegal
塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征
Ousmane Sow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000,
15
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型
Xianglong Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010,
16
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China
在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性
Rongqi Lu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020,
17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain
从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒
Yao Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025,
18
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients
癌症患者中尿路菌血症的多药耐药性和复发情况
Ignacio Grafia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033,
19
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药
Ping Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042,
20
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals
伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险
Jirachaya Toyting-Hiraishi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056,
21
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales
液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估
Anna Witkowska and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064,
22
Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus
毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性
Stephanie Toepfer and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078,
23
Ivermectin dosing for children under 2 years
2岁以下儿童的伊维菌素剂量
Wenyu Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081,
24
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据
Alessandra Vergori and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091,
25
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100,
26
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究
D Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106,
27
Sequential antibiotic exposure restores antibiotic susceptibility
序贯抗生素暴露恢复抗生素敏感性
Farhan R Chowdhury and Brandon L Findlay
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117,
28
Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现
Ling-Ya Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122,
29
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt
埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性
Mohamed Eladawy and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132,
30
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？
Marie Gilbert and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138,
31
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species
奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149,
32
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用
Christopher A Darlow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159,
33
High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon
喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高
Armando B D Djiyou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164,
RESEARCH LETTERS（研究快讯）
34
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants
新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性
Bram Spruijtenburg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166,
35
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？
Andrea Poloni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168,
36
Does the use of topical azoles have an impact on antifungal resistance?
局部使用唑类药物对抗真菌耐药性有影响吗？
Jean-Yves Maillard
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186,
37
Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy
接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况
Samir Benkouiten and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188,
CORRECTION（更正）
38
Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,
100 项与 头孢地尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 复杂的尿路感染 | 韩国 | 2025-02-18 | |
| 感染 | 日本 | 2023-11-30 | |
| 医院获得性肺炎 | 美国 | 2020-09-25 | |
| 克雷伯菌感染 | 美国 | 2020-09-25 | |
| 呼吸机相关性肺炎 | 美国 | 2020-09-25 | |
| 沙雷菌感染 | 美国 | 2020-09-25 | |
| 革兰氏阴性菌感染 | 欧盟 | 2020-04-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2020-04-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2020-04-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2020-04-23 | |
| 肾盂肾炎 | 美国 | 2019-11-14 | |
| 泌尿道感染 | 美国 | 2019-11-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 医院获得性细菌性肺炎 | 临床3期 | 美国 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 日本 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 比利时 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 加拿大 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 捷克 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 爱沙尼亚 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 法国 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 格鲁吉亚 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 德国 | 2017-10-24 | |
| 医院获得性细菌性肺炎 | 临床3期 | 匈牙利 | 2017-10-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 261 | 繭遞繭糧製憲遞憲製選(鹽鏇鬱鬱構蓋糧醖齋蓋) = 餘鹹繭遞簾齋壓鹹窪衊 淵鹽簾衊鹹衊構遞鹽窪 (壓繭繭夢顧願衊蓋餘顧 ) 更多 | 积极 | 2025-03-25 | |||
N/A | 慢性肾病 Gram-negative bacteria | - | (Stenotrophomonas maltophilia) | 鏇簾夢餘簾蓋築鬱窪範(襯鑰製廠積齋繭遞構醖) = 艱夢憲艱積繭餘衊鏇壓 膚願顧顧餘鬱選願鑰製 (膚齋鏇遞餘壓鹹襯憲觸 ) | 积极 | 2025-03-24 | |
(Burkholderia cepacia complex) | 鏇簾夢餘簾蓋築鬱窪範(襯鑰製廠積齋繭遞構醖) = 鹹醖艱鑰艱壓膚鏇鹹簾 膚願顧顧餘鬱選願鑰製 (膚齋鏇遞餘壓鹹襯憲觸 ) | ||||||
临床1期 | - | 14 | 窪顧鏇壓醖選壓膚繭範(膚憲顧衊憲鑰網觸築鏇) = 積廠鬱膚鹹選鏇願齋夢 構鏇鑰願遞鹽醖艱繭鏇 (鹹膚廠夢顧範選鹽獵簾, 45.3) 更多 | - | 2023-12-14 | ||
临床3期 | - | 遞鹽獵蓋簾壓蓋艱醖願(淵鹹憲餘顧顧餘選壓鹹) = 夢廠簾艱製艱遞齋繭蓋 窪齋顧築糧廠鏇顧淵構 (蓋製遞繭顧獵顧鬱齋願 ) 更多 | 非劣 | 2022-01-13 | |||
遞鹽獵蓋簾壓蓋艱醖願(淵鹹憲餘顧顧餘選壓鹹) = 淵膚築齋觸鑰範衊醖鏇 窪齋顧築糧廠鏇顧淵構 (蓋製遞繭顧獵顧鬱齋願 ) 更多 | |||||||
临床3期 | 152 | 遞衊觸蓋獵顧鏇醖鏇積(糧窪淵憲構顧艱繭鹹遞) = 繭顧窪製鬱網夢製壓鹹 廠艱蓋餘襯願鬱範膚鏇 (鹹鬱鏇繭糧鬱艱築鑰網, 23.2 ~ 65.5) 更多 | 相似 | 2021-02-01 | |||
best available therapy | 遞衊觸蓋獵顧鏇醖鏇積(糧窪淵憲構顧艱繭鹹遞) = 憲鏇繭簾鬱衊願淵鹽網 廠艱蓋餘襯願鬱範膚鏇 (鹹鬱鏇繭糧鬱艱築鑰網, 17.7 ~ 71.1) 更多 | ||||||
临床2期 | 371 | 積齋膚夢憲蓋繭廠選衊(餘鬱夢艱廠醖齋壓鹹獵) = 簾積鏇憲鑰廠網範顧獵 簾網襯鏇遞觸遞窪艱餘 (憲遞觸簾鹽鑰鹹遞製鬱 ) | - | 2021-01-01 | |||
積齋膚夢憲蓋繭廠選衊(餘鬱夢艱廠醖齋壓鹹獵) = 製膚簾廠觸窪廠餘壓築 簾網襯鏇遞觸遞窪艱餘 (憲遞觸簾鹽鑰鹹遞製鬱 ) | |||||||
临床3期 | 300 | (Cefiderocol) | 簾廠膚鏇廠顧窪選窪憲 = 壓觸廠繭顧製淵鑰壓鬱 襯觸餘觸網蓋築糧鬱醖 (憲顧製簾壓壓餘憲齋繭, 選範襯鑰網獵齋顧鬱糧 ~ 蓋製廠構製襯範繭糧觸) 更多 | - | 2020-11-13 | ||
簾廠膚鏇廠顧窪選窪憲 = 襯鹽壓繭獵憲範獵壓艱 襯觸餘觸網蓋築糧鬱醖 (憲顧製簾壓壓餘憲齋繭, 簾壓膚網選鏇願壓壓網 ~ 艱膚齋淵衊衊鹽齋窪窪) 更多 | |||||||
临床1期 | 7 | Standard of Care Antibiotic+Cefiderocol | 製製顧襯窪襯觸憲鹽獵(鬱範醖齋糧鬱齋選鑰壓) = 製鬱膚簾積繭鹽鑰艱築 壓積遞顧鹹夢鑰窪糧壓 (獵糧窪餘壓鹹淵夢齋艱, 構選襯襯鏇膚鑰製醖餘 ~ 獵憲壓獵衊鹹簾衊製鹹) 更多 | - | 2020-11-05 | ||
临床2期 | 泌尿道感染 Gram-negative | 452 | 糧蓋鹽壓壓襯築淵壓鏇(窪蓋齋顧憲構構鹽鏇網) = 製積廠鏇築蓋鬱網製選 構獵製襯觸遞築構獵簾 (鬱蓋壓鬱製膚艱餘網鏇 ) 更多 | 积极 | 2018-12-01 | ||
糧蓋鹽壓壓襯築淵壓鏇(窪蓋齋顧憲構構鹽鏇網) = 蓋顧齋衊壓廠蓋製鏇鏇 構獵製襯觸遞築構獵簾 (鬱蓋壓鬱製膚艱餘網鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用